So far, the Jarvik 2000 FlowMakerŽ has been used to treat more than 200 patients in the U.S., Europe and Asia. Of those, roughly 79 percent received the Jarvik 2000 as a bridge to transplant and 21 percent as a permanent implant, with a number of patients in each group being very ill, near-death cases. Nearly 70 percent of those patients treated as bridge-to-transplant have either undergone transplantation already or are currently being supported by the Jarvik 2000.
For lifetime use, the Jarvik 2000 has also had excellent success treating a target population of patients suffering chronic heart failure due to a prior heart attack or cardiomyopathy. Many have been rehabilitated to a dramatically improved life at home, and in some cases patients have returned to work.
As important as these statistics are, the Jarvik 2000 is aimed at giving the patient two things not always reflected in numbers: improved quality of life and hope for the future. A patient's quality of life improves dramatically after recovery from surgery. A patient's hope for the future rests on the collective experience of those successfully supported by the Jarvik 2000 and other ventricular assist devices.